Last 7 days
-5.5%
Last 30 days
-16.1%
Last 90 days
-22.7%
Trailing 12 Months
-28.3%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
UNH | 441.5B | 324.2B | -6.04% | -5.61% | 21.94 | 1.36 | 12.71% | 16.40% |
CVS | 95.1B | 322.5B | -16.10% | -28.31% | 22.93 | 0.3 | 10.39% | -47.55% |
CI | 91.1B | 180.5B | -9.45% | 16.50% | 13.64 | 1.92 | 3.70% | 24.58% |
HUM | 62.6B | 92.9B | -3.60% | 10.39% | 22.3 | 0.67 | 11.81% | -4.33% |
CNC | 34.4B | 144.5B | -13.05% | -25.78% | 28.66 | 0.24 | 14.74% | -10.76% |
MID-CAP | ||||||||
OPCH | 5.6B | 3.9B | 7.58% | 19.99% | 37.42 | 1.43 | 14.72% | 7.62% |
LHCG | 5.2B | 2.3B | 3.17% | 35.63% | 86.23 | 2.28 | 2.85% | -58.05% |
HQY | 4.9B | 831.2M | -11.67% | 3.11% | -82.63 | 5.84 | 12.11% | -862.52% |
CVET | 2.9B | 4.6B | 0.72% | 13.28% | -225.79 | 0.63 | 2.45% | 84.88% |
PDCO | 2.6B | 6.4B | -14.06% | -14.67% | 13.12 | 0.4 | -0.52% | 17.01% |
SMALL-CAP | ||||||||
TVTY | 1.6B | - | 0.59% | 17.88% | 18.77 | 3.24 | - | - |
ADUS | 1.6B | 951.1M | -7.28% | 30.41% | 35.03 | 1.7 | 10.02% | 1.99% |
RDNT | 1.2B | 1.4B | 12.22% | 10.36% | 115.9 | 0.86 | 8.74% | -56.93% |
BKD | 449.4M | 2.8B | -3.12% | -59.80% | -1.88 | 0.16 | 2.43% | -140.13% |
JYNT | 242.8M | 96.2M | 2.80% | -48.48% | 898.97 | 2.52 | 26.92% | -98.46% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 2.3% | 322,467 | 315,225 | 307,860 | 299,840 | 292,111 |
Operating Expenses | 1.6% | 38,094 | 37,490 | - | - | - |
EBITDA | 13.2% | 12,162 | 10,745 | 17,460 | 17,269 | - |
EBITDA Margin | 10.6% | 0.04* | 0.03* | 0.06* | 0.06* | - |
Earnings Before Taxes | 37.6% | 5,628 | 4,089 | 10,690 | 10,396 | 10,420 |
EBT Margin | 34.5% | 0.02* | 0.01* | 0.03* | 0.03* | - |
Interest Expenses | -2.4% | 2,287 | 2,343 | 2,379 | 2,432 | 2,503 |
Net Income | 31.1% | 4,149 | 3,164 | 8,178 | 8,008 | 7,910 |
Net Income Margin | 28.2% | 0.01* | 0.01* | 0.03* | 0.03* | - |
Free Cahsflow | -31.0% | 13,450 | 19,498 | 15,868 | 16,194 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -1.3% | 228,275 | 231,212 | 230,279 | 232,873 | 232,999 |
Current Assets | -3.9% | 65,682 | 68,341 | 62,142 | 61,483 | 60,008 |
Cash Equivalents | -24.7% | 12,945 | 17,197 | 12,116 | 8,442 | 9,408 |
Inventory | 5.7% | 19,090 | 18,058 | 17,375 | 18,160 | 17,760 |
Net PPE | 2.0% | 12,873 | 12,626 | 12,764 | 12,844 | 12,896 |
Goodwill | 0.1% | 78,150 | 78,086 | 78,560 | 79,060 | 79,121 |
Liabilities | -2.0% | 156,960 | 160,201 | 154,773 | 158,733 | 157,618 |
Current Liabilities | -3.7% | 69,736 | 72,409 | 68,457 | 69,780 | 67,807 |
Long Term Debt | -0.7% | 50,476 | 50,848 | 50,797 | 52,063 | 51,971 |
Shareholder's Equity | 0.5% | 71,015 | 70,683 | 75,506 | 74,140 | 75,075 |
Retained Earnings | 2.9% | 56,145 | 54,571 | 58,710 | 56,488 | 54,906 |
Accumulated Depreciation | - | 20,654 | - | - | - | - |
Shares Outstanding | -1.1% | 1,300 | 1,315 | 1,312 | 1,306 | 1,322 |
Minority Interest | -8.5% | 300 | 328 | 322 | 310 | 306 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -26.9% | 16,177 | 22,134 | 18,532 | 18,936 | 18,265 |
Share Based Compensation | -6.7% | 447 | 479 | 488 | 486 | 484 |
Cashflow From Investing | 20.7% | -5,047 | -6,368 | -6,410 | -5,387 | -5,261 |
Cashflow From Financing | 6.5% | -10,516 | -11,243 | -9,955 | -10,821 | -11,356 |
Dividend Payments | 2.1% | 2,907 | 2,848 | 2,781 | 2,691 | 2,625 |
Buy Backs | 75.0% | 3,500 | 2,000 | 2,000 | 2,000 | 0.00 |
58.1%
14.2%
0%
Y-axis is the maximum loss one would have experienced if CVS Health was unfortunately bought at previous high price.
5.8%
-1.6%
5.6%
10.8%
FIve years rolling returns for CVS Health.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | added | 3.06 | 55,130 | 8,103,130 | 0.23% |
2023-03-13 | Claro Advisors LLC | added | 18.81 | 216,324 | 1,327,320 | 0.43% |
2023-03-10 | MATHER GROUP, LLC. | reduced | -3.66 | -63,602 | 1,016,400 | 0.02% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -5.03 | -8,247,480 | 106,282,000 | 0.12% |
2023-03-08 | Capital Asset Advisory Services LLC | reduced | -7.88 | -127,522 | 1,373,480 | 0.11% |
2023-03-08 | SHEETS SMITH WEALTH MANAGEMENT | reduced | -2.76 | -61,984 | 1,191,020 | 0.19% |
2023-03-07 | Great Lakes Retirement, Inc. | new | - | 648,748 | 648,748 | 0.17% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 5.11 | 1,905,000 | 72,371,000 | 0.36% |
2023-03-03 | TIAA, FSB | added | 10.8 | 411,003 | 5,382,000 | 0.02% |
2023-03-03 | Crumly & Associates Inc. | reduced | -5.02 | -46,050 | 591,950 | 0.22% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 8.94% | 117,533,372 | SC 13G/A | |
Feb 07, 2023 | blackrock inc. | 7.4% | 96,668,258 | SC 13G/A | |
Feb 09, 2022 | vanguard group inc | 8.28% | 109,236,922 | SC 13G/A | |
Feb 01, 2022 | blackrock inc. | 7.1% | 93,556,500 | SC 13G/A | |
Feb 10, 2021 | vanguard group inc | 8.05% | 105,383,923 | SC 13G/A | |
Jan 29, 2021 | blackrock inc. | 7.1% | 92,478,369 | SC 13G/A | |
Feb 12, 2020 | vanguard group inc | 8.05% | 104,808,202 | SC 13G/A | |
Feb 05, 2020 | blackrock inc. | 7.2% | 94,158,010 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 123.17 68.31% | 150.44 105.58% | 201.10 174.80% | 258.39 253.09% | 323.05 341.45% |
Current Inflation | 113.28 54.80% | 136.37 86.35% | 178.69 144.18% | 226.45 209.44% | 280.46 283.25% |
Very High Inflation | 101.12 38.18% | 119.41 63.17% | 152.32 108.14% | 189.45 158.88% | 231.59 216.47% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 07, 2023 | DFAN14A | DFAN14A | |
Mar 01, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 4 | Insider Trading | |
Feb 21, 2023 | 8-K | Current Report | |
Feb 15, 2023 | 3 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-02-28 | Clark James David | sold (taxes) | -14,953 | 83.54 | -179 | svp, cont & chief acct officer |
2023-02-28 | Chaguturu Sreekanth K | sold (taxes) | -10,024 | 83.54 | -120 | evp and chief medical officer |
2023-02-28 | Khichi Samrat S. | acquired | 3,999,980 | 83.54 | 47,881 | evp, cpo and general counsel |
2023-02-28 | Joyner J. David | acquired | 1,999,950 | 83.54 | 23,940 | evp&president-pharmacyservices |
2023-02-27 | Chaguturu Sreekanth K | sold (taxes) | -27,274 | 85.77 | -318 | evp and chief medical officer |
2023-02-27 | Havanec Laurie P. | sold (taxes) | -347,025 | 85.77 | -4,046 | evp and chief people officer |
2023-02-27 | Shah Prem S | sold (taxes) | -19,384 | 85.77 | -226 | evp and co-president of retail |
2023-02-27 | PELUSO MICHELLE A | sold (taxes) | -1,055,310 | 85.77 | -12,304 | evp and co-president of retail |
2023-02-02 | PELUSO MICHELLE A | acquired | - | - | 192,554 | evp and co-president of retail |
2023-02-02 | Lynch Karen S | acquired | - | - | 206,610 | president and ceo |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenues: | ||||
Premiums | $ 21,003 | $ 18,984 | $ 63,894 | $ 56,927 |
Net investment income | 201 | 246 | 515 | 832 |
Total revenues | 81,159 | 73,794 | 238,621 | 215,507 |
Operating costs: | ||||
Cost of products sold | 50,365 | 45,011 | 145,164 | 129,425 |
Benefit costs | 17,419 | 16,081 | 52,976 | 47,686 |
Opioid litigation charges | 5,220 | 0 | 5,704 | 0 |
Loss on assets held for sale | 2,480 | 0 | 2,521 | 0 |
Goodwill impairment | 0 | 431 | 0 | 431 |
Operating expenses | 9,606 | 9,210 | 28,128 | 27,001 |
Total operating costs | 85,090 | 70,733 | 234,493 | 204,543 |
Operating income (loss) | (3,931) | 3,061 | 4,128 | 10,964 |
Interest expense | 566 | 602 | 1,735 | 1,895 |
Loss on early extinguishment of debt | 0 | 363 | 0 | 363 |
Other income | (41) | (49) | (126) | (144) |
Income (loss) before income tax provision | (4,456) | 2,145 | 2,519 | 8,850 |
Income tax provision (benefit) | (1,047) | 558 | 654 | 2,248 |
Net income (loss) | (3,409) | 1,587 | 1,865 | 6,602 |
Net (income) loss attributable to noncontrolling interests | (7) | 11 | (18) | 2 |
Net income (loss) attributable to CVS Health | $ (3,416) | $ 1,598 | $ 1,847 | $ 6,604 |
Net income (loss) per share attributable to CVS Health: | ||||
Basic (in dollars per share) | $ (2.60) | $ 1.21 | $ 1.41 | $ 5.01 |
Diluted (in dollars per share) | $ (2.60) | $ 1.20 | $ 1.40 | $ 4.98 |
Weighted average shares outstanding: | ||||
Basic (in shares) | 1,315 | 1,321 | 1,313 | 1,318 |
Diluted (in shares) | 1,315 | 1,329 | 1,324 | 1,326 |
Dividends declared per share (in dollars per share) | $ 0.55 | $ 0.50 | $ 1.65 | $ 1.50 |
Cost, Product and Service [Extensible List] | Products | Products | Products | Products |
Products | ||||
Revenues: | ||||
Revenues | $ 57,643 | $ 51,853 | $ 166,959 | $ 149,765 |
Services | ||||
Revenues: | ||||
Revenues | $ 2,312 | $ 2,711 | $ 7,253 | $ 7,983 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
---|---|---|
Assets: | ||
Cash and cash equivalents | $ 17,197 | $ 9,408 |
Investments | 2,792 | 3,117 |
Accounts receivable, net | 26,317 | 24,431 |
Inventories | 18,058 | 17,760 |
Assets held for sale | 1,498 | 0 |
Other current assets | 2,479 | 5,292 |
Total current assets | 68,341 | 60,008 |
Long-term investments | 20,565 | 23,025 |
Property and equipment, net | 12,626 | 12,896 |
Operating lease right-of-use assets | 18,270 | 19,122 |
Goodwill | 78,086 | 79,121 |
Intangible assets, net | 25,157 | 29,026 |
Separate accounts assets | 3,318 | 5,087 |
Other assets | 4,849 | 4,714 |
Total assets | 231,212 | 232,999 |
Liabilities: | ||
Accounts payable | 13,925 | 12,544 |
Pharmacy claims and discounts payable | 19,161 | 17,330 |
Health care costs payable | 10,351 | 8,808 |
Policyholders’ funds | 1,642 | 4,301 |
Accrued expenses | 19,423 | 17,670 |
Other insurance liabilities | 4,561 | 1,303 |
Current portion of operating lease liabilities | 1,687 | 1,646 |
Current portion of long-term debt | 1,363 | 4,205 |
Liabilities held for sale | 296 | 0 |
Total current liabilities | 72,409 | 67,807 |
Long-term operating lease liabilities | 17,174 | 18,177 |
Long-term debt | 50,848 | 51,971 |
Deferred income taxes | 3,508 | 6,270 |
Separate accounts liabilities | 3,318 | 5,087 |
Other long-term insurance liabilities | 6,175 | 6,402 |
Other long-term liabilities | 6,769 | 1,904 |
Total liabilities | 160,201 | 157,618 |
Shareholders’ equity: | ||
Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding | 0 | 0 |
Common stock, par value $0.01: 3,200 shares authorized; 1,757 shares issued and 1,315 shares outstanding at September 30, 2022 and 1,744 shares issued and 1,322 shares outstanding at December 31, 2021 and capital surplus | 48,047 | 47,377 |
Treasury stock, at cost: 442 shares at September 30, 2022 and 422 shares at December 31, 2021 | (30,326) | (28,173) |
Retained earnings | 54,571 | 54,906 |
Accumulated other comprehensive income (loss) | (1,609) | 965 |
Total CVS Health shareholders’ equity | 70,683 | 75,075 |
Noncontrolling interests | 328 | 306 |
Total shareholders’ equity | 71,011 | 75,381 |
Total liabilities and shareholders’ equity | $ 231,212 | $ 232,999 |